**Immunization Test Tool Release Notes for Version 2.1.0 November 20, 2024**

**Data**

| **Test Case / Message Profile** | **Issue** | **Resolution** |
| --- | --- | --- |
| For Z22 messages | Per the CDC, the following **Unit of Sale NDC(**s) has/have been added:   * 00006-4347-01 for **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * 00006-4347-02 for **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * 50090-3781-00 for Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use (HAVRIX) * 50632-0016-02 for Typhoid vaccine, live, oral (Vivotif) * 00069-2465-01 for RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)** * 00069-2465-10 for RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)** * 50632-0001-03 JYNNEOS - Smallpox/Monkeypox vaccine Bavarian Nordic A/S (JYNNEOS) * 70460-0004-01 cholera, live attenuated (Vaxchora) * 69401-0000-02 typhoid, oral (Vivotif)   Per the CDC, the following **Unit of Sale** NDC(s) has/have been added for **new Influenza Vaccines for 2024/2025 Season**   * 58160-0884-52 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUARIX) * 70461-0654-03 for Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * 33332-0124-10 for Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (Afluria) * 19515-0810-52 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLULAVAL) * 49281-0641-15 for Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * 49281-0424-50 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * 49281-0724-10 for Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use (FLUBLOK TRIVALENT NORTHERN HEMISPHERE) * 49281-0124-65 for Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use (FLUZONE HIGH DOSE NORTHERN HEMISPHERE) * 70461-0554-10 for Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * 33332-0024-03 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (Afluria) * 70461-0024-03 for Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use (FLUAD) * 66019-0311-10 for FluMist (MedImmune, Inc. AstraZeneca)   Per the CDC, the following **Unit of Sale NDC(**s) have been added for new **Fall 2024 COVID-19 vaccines**:   * 80631-0107-10 for NOVAVAX COVID-19 VACCINE, ADJUVANTED * 80777-0110-96 for Spikevax (Moderna) * 80777-0110-93 for Spikevax (Moderna) * 00069-2432-10 for Comirnaty (Pfizer) * 80777-0291-81 for Moderna COVID-19 Vaccine * 59267-4438-02 for Pfizer-BioNTech Covid-19 Vaccine * 59267-4426-02 for Pfizer-BioNTech Covid-19 Vaccine * 80777-0291-80 for Moderna COVID-19 Vaccine | Update(s) has/have been made to the **NDC Unit of Sale Value Set** in the Immunization Test Suite  Added:   * **Code**: 00006-4347-01 * **Code System**: NDC * **Description**: **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * **Code**: 00006-4347-02 * **Code System**: NDC * **Description**: **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * **Code**: 58160-0884-52 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUARIX) * **Code**: 70461-0654-03 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * **Code**: 33332-0124-10 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (Afluria) * **Code**: 19515-0810-52 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLULAVAL) * **Code**: 49281-0641-15 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0424-50 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0724-10 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use (FLUBLOK TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0124-65 * **Code System**: NDC * **Description**: Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use (FLUZONE HIGH DOSE NORTHERN HEMISPHERE) * **Code**: 70461-0554-10 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * **Code**: 33332-0024-03 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (Afluria) * **Code**: 70461-0024-03 * **Code System**: NDC * **Description**: Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use (FLUAD) * **Code**: 50090-3781-00 * **Code System**: NDC * **Description**: Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use (HAVRIX)      * **Code**: 50632-0016-02 * **Code System**: NDC * **Description**: Typhoid vaccine, live, oral (Vivotif) * **Code**: 00069-2465-01 * **Code System**: NDC * **Description**: RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)** * **Code**: 00069-2465-10 * **Code System**: NDC * **Description**: RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)** * **Code**: 80631-0107-10 * **Code System**: NDC * **Description**: NOVAVAX COVID-19 VACCINE, ADJUVANTED * Code: 80777-0110-96 * **Code System**: NDC * **Description**: Spikevax (Moderna) * Code: 80777-0110-93 * **Code System**: NDC * **Description**: Spikevax (Moderna) * Code: 00069-2432-10 * **Code System**: NDC * **Description**: Comirnaty (Pfizer) * **Code**: 80777-0291-81 * **Code System**: NDC * **Description**: Moderna COVID-19 Vaccine * **Code**: 59267-4438-02 * **Code System**: NDC * **Description**: Pfizer-BioNTech Covid-19 Vaccine * **Code**: 59267-4426-02 * **Code System**: NDC * **Description**: Pfizer-BioNTech Covid-19 Vaccine * **Code**: 80777-0291-80 * **Code System**: NDC * **Description**: Moderna COVID-19 Vaccine * **Code**: 66019-0311-10 * **Code System**: NDC * **Description**: FluMist (MedImmune, Inc. AstraZeneca) * **Code**: 50632-0001-03 * **Code System**: NDC * **Description**: Smallpox/Monkeypox vaccine Bavarian Nordic A/S (JYNNEOS) * **Code**: 70460-0004-01 * **Code System**: NDC * **Description**: cholera, live attenuated (Vaxchora) * **Code**: 69401-0000-02 * **Code System**: NDC * **Description**: typhoid, oral (Vivotif) |
| For Z22 messages | Per the CDC, the following **Unit of Use NDC(s)** has/have been added:   * 00006-4347-99 for **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * 50090-3781-01 for Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use (HAVRIX) * 50632-0016-04 for Typhoid vaccine, live, oral (Vivotif) * 00069-2465-19 for RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)**   Per the CDC, the following **Unit of Use NDC**(s) has/have been added for **new Influenza Vaccines for 2024/2025 Season**   * 58160-0884-52 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUARIX) * 70461-0654-04 for Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * 33332-0124-11 for Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (Afluria) * 19515-0810-41 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLULAVAL) * 49281-0641-78 for Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * 49281-0424-88 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * 49281-0724-88 for Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use (FLUBLOK TRIVALENT NORTHERN HEMISPHERE) * 49281-0124-88 for Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use (FLUZONE HIGH DOSE NORTHERN HEMISPHERE) * 70461-0554-11 for Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * 33332-0024-04 for Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (Afluria) * 70461-0024-04 for Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use (FLUAD) * 66019-311-00 for FluMist (MedImmune, Inc. AstraZeneca)   Per the CDC, the following **Unit of Use NDC(**s) have been added for new **Fall 2024 COVID-19 vaccines**:   * 80631-0107-01 for NOVAVAX COVID-19 VACCINE, ADJUVANTED * 80777-0110-01 for Spikevax (Moderna) * 00069-2432-01 for Comirnaty (Pfizer) * 80777-0291-09 for Moderna COVID-19 Vaccine * 59267-4438-01 for Pfizer-BioNTech Covid-19 Vaccine * 59267-4426-01 for Pfizer-BioNTech Covid-19 Vaccine | Update(s) has/have been made to the **NDC Unit of Use Value Set** in the Immunization Test Suite  Added:   * **Code**: 00006-4347-99 * **Code System**: NDC * **Description**: **Pneumococcal Conjugate 21 Valent Vaccine (PCV 21) (**CAPVAXIVE) * **Code**: 58160-0884-52 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUARIX) * **Code**: 70461-0654-04 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * **Code**: 33332-0124-11 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (Afluria) * **Code**: 19515-0810-41 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLULAVAL) * **Code**: 49281-0641-78 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use **and** Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0424-88 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (FLUZONE TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0724-88 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use (FLUBLOK TRIVALENT NORTHERN HEMISPHERE) * **Code**: 49281-0124-88 * **Code System**: NDC * **Description**: Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use (FLUZONE HIGH DOSE NORTHERN HEMISPHERE) * **Code**: 70461-0554-11 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, antibiotic free, 0.5 mL dosage, for intramuscular use (Flucelvax) * **Code**: 33332-0024-04 * **Code System**: NDC * **Description**: Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use (Afluria) * **Code**: 70461-0024-04 * **Code System**: NDC * **Description**: Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use (FLUAD) * **Code**: 50090-3781-01 * **Code System**: NDC * **Description**: Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use (HAVRIX) * **Code**: 50632-0016-04 * **Code System**: NDC * **Description**: Typhoid vaccine, live, oral (Vivotif) * **Code**: 00069-2465-19 * **Code System**: NDC * **Description**: RSV, bivalent, protein subunit RSVpreF, diluent reconstituted, 0.5 mL, PF **(Abrysvo)** * **Code**: 80631-0107-01 * **Code System**: NDC * **Description**: NOVAVAX COVID-19 VACCINE, ADJUVANTED * Code: 80777-0110-01 * **Code System**: NDC * **Description**: Spikevax (Moderna) * Code: 00069-2432-01 * **Code System**: NDC * **Description**: Comirnaty (Pfizer) * Code: 80777-0291-09 * **Code System**: NDC * **Description**: Moderna COVID-19 Vaccine * Code: 59267-4438-01 * **Code System**: NDC * **Description**: Pfizer-BioNTech Covid-19 Vaccine * Code: 59267-4426-01 * **Code System**: NDC * **Description**: Pfizer-BioNTech Covid-19 Vaccine * Code: 66019-311-00 * **Code System**: NDC * **Description**: FluMist (MedImmune, Inc. AstraZeneca) |
| For Z22, Z32, and Z42 messages | Per the CDC, the following addition(s)/modification(s) has/have been made to the **CVX** table:  Added:   * CVX code 327 for Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free | Update(s) has/have been made to the **CVX** **Value Set** in the Immunization Test Suite  Added:   * **Code**: 327 * **Code System**: CVX * **Description**: Pneumococcal conjugate vaccine, 21 valent (PCV21), polysaccharide CRM197 conjugate, preservative free |
| **ONC 2015 Test Plan**  **Test Case**:  IZ-AD-1\_Admin\_Child  **Test Step**:  IZ-AD-1.1\_Send\_V04\_Z22 | The VXU Example Message includes the retired UoU NDC “49281-0560-05” for Pentacel in RXA-5.1:  RXA|0|1|20150624||**49281-0560-05**^Pentacel^NDC|0.5|mL^mL^UCUM||00^New Record^NIP001|7824^Jackson^Lily^Suzanne^^^^^NIST-PI-1^L^^^PRN|^^^NIST-Clinic-1||||526434|20150722|PMC^Sanofi Pasteur^MVX|||CP|A | The retired UoU NDC “49281-0560-05” has been changed to active UoU NDC “49281-0561-01” for Pentacel in RXA-5.1 in the VXU Example Message:  RXA|0|1|20150624||**49281-0561-01**^Pentacel^NDC|0.5|mL^mL^UCUM||00^New Record^NIP001|7824^Jackson^Lily^Suzanne^^^^^NIST-PI-1^L^^^PRN|^^^NIST-Clinic-1||||526434|20150722|PMC^Sanofi Pasteur^MVX|||CP|A  The retired NDCs (49281-0510-05, 49281-0545-15, 49281-0560-05) in the Value-Test Case Fixed List for the RXA-5.1 field for Pentacel have been deleted. |

| **Message Profile** | **Issue** | | **Resolution** |
| --- | --- | --- | --- |
| For Z22, Z32, Z42 messages | Per the CDC, the following VIS document(s) and VIS Code(s) has/have been added: | | The new VIS document(s) with **Description** and associated VIS **Code** has/have been added to the **PHVS\_VISBarcodes\_IIS Value Set** in the Immunization Test Suite |
|  | **Document Type Description (New)** | **VIS Fully-encoded Test String** |
|  | COVID-19 Pfizer BioNTech EUA Recipient-Caregiver Fact Sheet - 6 months through 11 years | 253088698300058511240801 |
|  | COVID-19 Moderna EUA Recipient-Caregiver Fact Sheet - 6 months through 11 years | 253088698300061511240801 |
|  | COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet - 12 years and older | 253088698300037011240801 |

**Specific Validation**

| **Issue** | **Resolution** |
| --- | --- |
| In the Immunization Test Suite:   * For **Z32, Z42**: Usage for **RXA-9** (Administration Notes) is C(R/O)   + Predicate associated with RXA-9 is “If the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA'.” * For **Z32**: Usage for **RXA-15** (Substance Lot Number) is C(R/O)   + Predicate associated with RXA-15 is “If RXA-9.1 (Identifier) is valued AND if RXA-20 (Completion Status) is valued AND if the value of RXA-9.1 (Identifier) is ‘00’ AND if the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA'.” * For **Z42**: Usage for **RXA-15** (Substance Lot Number) is O * For **Z32, Z42**: Usage for **RXA-17** (Substance Manufacturer Name) is C(R/O)   + Predicate associated with RXA-17 in Z32 is “If RXA-9.1 (Identifier) is valued AND if the value of RXA-9.1 (Identifier) is '00'.”   + Predicate associated with RXA-17 in Z42 is “If the value of RXA-9.1 (Identifier) is '00' AND if the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA'.”   These modifications have been requested by AIRA to accommodate needs of the user community:   * Add new coded values for Race & Ethnicity: ‘UNK’, ‘ASKU’, and ‘PHC1175’ in the CDCREC Value Sets for Z22, Z32, Z42 * For RXA-9 in Z32 & Z42, relax Usage from C(R/O) to O; delete Predicate * For RXA-15   + In Z32, change Usage from C(R/O) to C(RE/X); change Predicate to “If the value of RXA-20 (Completion Status) is either ‘CP’ or ‘PA’ “   + In Z42, change Usage from O to C(RE/X); add Predicate “If the value of RXA-20 (Completion Status) is either ‘CP’ or ‘PA’ “ * For RXA-17 in Z32 & Z42, change Usage from C(R/O) to C(RE/X); change Predicate to “If the value of RXA-20 (Completion Status) is either ‘CP’ or ‘PA’ “ * Add new coded value “PRS” (Personal) for Telecommunication Use Code to table HL70201\_IZ | Immunization Test Suite has been modified including:   * For **Z22, Z32, Z42**: Coded values for Race & Ethnicity have been added in the CDCREC\_R\_IZ and CDCREC\_E\_IZ Value Sets:   + UNK = Unknown   + ASKU = Asked but unknown   + PHC1175 = Refused to answer * For **Z32, Z42**: Usage for **RXA-9** (Administration Notes) has been changed to O; and the Predicate has been deleted * For **Z32, Z42**: Usage for **RXA-15** (Substance Lot Number) has been changed to C(RE/X), and the Predicate has been changed to “If RXA-20 (Completion Status) is valued AND if the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA'.” * For **Z32, Z42**: Usage for **RXA-17** (Substance Manufacturer Name) has been changed to C(RE/X), and the Predicate has been changed to “If the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA'.” * For **Z22, Z34, Z44, Z31, Z32, Z33, Z42**, coded value “PRS” (Personal) for Telecommunication Use Code has been added to table **HL70201\_IZ**   And other associated modifications have been made including:   * For **Z32, Z42**: Datatype for **RXA-9** (Administration Notes) has been reverted back to base standard, and Value Set has been reverted back to base standard (NIP001 has been removed) * For **Z32, Z42**: These Conformance Statements for **RXA-9** (Administration Notes) have been removed   + IZ-31 : If RXA-20 (Completion Status) is valued and the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA' then the value of RXA-9.1 (Identifier) SHALL be one of codes listed in the Value Set: NIP001.   + IZ-47 : If RXA-20 (Completion Status) is not valued or the value of RXA-20 (Completion Status) is not one of List Values: 'CP','PA' then RXA-9.1 (Identifier) SHALL NOT be valued. * For **Z32, Z42**: The Predicate for **RXA-10** (Administering Provider) has been changed to “If the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA’” * For **Z32, Z42**: The Predicate for **RXA-11** (Administered-at Location) has been changed to “If the value of RXA-20 (Completion Status) is one of List Values: 'CP','PA’” |
| In the Immunization Test Suite for **MSA-1** (Acknowledgement Code) in the **ACK Z23** message, the associated **HL70008\_IZ** table includes the following codes, which are not supported in the Release 1.5 2014 Immunization Implementation Guide:   * CA - Enhanced mode: Accept acknowledgment: Commit Accept * CE - Enhanced mode: Accept acknowledgment: Commit Error * CR - Enhanced mode: Accept acknowledgment: Commit Reject | The **HL70008\_IZ** table has been modified: the CA, CE, CR codes have been deleted. |
| In the Immunization Test Suite for **OBX-5.1** (Observation Value) in the **VXU Z22** message [when the value of **OBX-3.1** (Identifier) is **64994-7** (Vaccine funding program eligibility category) and the value of **OBX-2** (Value Type) is **'CE'**], the associated **HL70064\_IZ** table incorrectly includes the following non-code:   |  |  | | --- | --- | | **Code** | **Description** | | **\*\*\*** | Specific state codes | | The **HL70064\_IZ** table has been modified: the \*\*\* non-code and Description have been deleted. |

**User Interface**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**Core Functionality**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**Documentation**

| **Issue** | **Resolution** |
| --- | --- |
| None |  |

**SOAP Functionality**

| **Test Case** | **Issue** | **Resolution** |
| --- | --- | --- |
| None |  |  |

**Improvements/Features**

|  |
| --- |
| None |

**Issues for a Future Release**

| **Test Case/if Applicable** | **Issue** |
| --- | --- |
| All Test Steps with a VXU message | In a VXU Context-based message where there are multiple OBX segments for each Order Group, if an OBX segment has OBX-3.1 populated with the 69764-9 LOINC code and has OBX-5.1 populated with an incorrect VIS ID, the Test Tool issues an Error notification that indicates   * in the **Path** information the VXU Order Group (e.g., “VXU\_V04.ORDER[1]”) within which the OBX with the error is contained and * in the **Line #** information the line number listed in the Message Content window for the ORC segment in that Order Group. * In the **Description** information that an Error has been found due to there being no OBX segment where OBX-3.1 is populated with the 69764-9 LOINC code and OBX-5.1 is populated with [an expected VIS ID] within in this Order Group.   The Path, Line #, and Description information may or may not be meaningful enough for a Tester to determine which OBX segment contains the VIS ID error.  The Tool will be modified to make the Error notification more specific and meaningful. |
| Context-free Data Quality Assurance (DQA) function | The DQA tab in the Context-free / VXU Z22 function has been removed in order to update the capability. The Tool will be modified with an updated version.  (Demonstration of how DQA is intended to function has been deleted from the updated Tool Tutorial.) |